## Edgar Filing: Sage Therapeutics, Inc. - Form 4

Sage Therape Form 4	eutics, Inc.											
May 29, 201								0.45 A				
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								Т	OMB APPROVAL			
<b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b> Washington, D.C. 20549							N OMB Number:	3235-0287				
Check thi if no long subject to Section 1 Form 4 o Form 5	6. Filed pur	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,							January 31, 2005 average irs per . 0.5			
obligation may cont <i>See</i> Instru 1(b). (Print or Type F	inue. Section 17(			•	•	mpany Act ny Act of 1	t of 1935 or Section 1940	on				
(I fint of Type I	(esponses)											
1. Name and Address of Reporting Person <u>*</u> STARR KEVIN P			2. Issuer Name <b>and</b> Ticker or Trading Symbol Sage Therapeutics, Inc. [SAGE]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
											(Last) (First) (Middle) C/O SAGE THERAPEUTICS,	
	IRST STREET	~,	03/20/2	2012			below)	below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>						
CAMBRID	GE, MA 02142						Person	where than one R	epotting			
(City)	(State)	(Zip)	Tal	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned			
	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, Amount	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(D) The						
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities bene	-	-	-					
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)			

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

(Instr. 3)	Price of Derivative Security	(Month/Day/Ye	ear) (Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				(
			Code V	(A) (D)	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	\$ 73.13	05/28/2015	А	13,922	<u>(1)</u>	05/28/2025	Common Stock	13,922

## **Reporting Owners**

 Reporting Owner Name / Address
 Relationships

 Director
 10% Owner
 Officer
 Other

 STARR KEVIN P

 C/O SAGE THERAPEUTICS, INC.
 215 FIRST STREET

 CAMBRIDGE, MA 02142

 Signatures

 /s/ Laurie Burlingame, as Attorney-in-Fact for Kevin P.<br/>Starr
 05/29/2015

 Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in full on May 28, 2016, subject to continued service through such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.